Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103721 | 0.92 | DPP4 (0.45) | CHRM4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3095092 | 0.87 | HPGD (0.50) | MAPTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL3101108 | 0.87 | MAPT (0.47) | MAPTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL3109861 | 0.85 | HPGD (0.53) | MAPTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL3101036 | 0.85 | HPGD (0.53) | MAPTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL3224721 | 0.84 | MAPT (0.45) | MAPTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL3103803 | 0.83 | SMN1; SMN2 (0.59) | CHRM4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3098642 | 0.83 | NPY5R (0.55) | MAPTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL3096412 | 0.79 | CHRM4 (0.45) | CHRM4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3099010 | 0.77 | CHRM4 (0.47) | CHRM4MAPTALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | claimed |
| EP-1768959-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | claimed |
| WO-2006004793-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-12 | — | — | WO | claimed |
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-29 | — | — | US | claimed |
| US-8604190-B2 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-10 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| EP-1768959-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006004793-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | VDAC1, HVCN1, TRPV1 | CHRM4 924/4885MAPT 4524/4885SMN1; SMN2 4542/4885 |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | VDAC1, HVCN1, TRPV1 | CHRM4 924/4885MAPT 4524/4885SMN1; SMN2 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.